Cantargia Ab · OMXSTO:CANTA
Cantargia Ab — Q4 2020 Earnings Presentation
18 slides from Cantargia Ab's earnings presentation, Feb 25, 2021
Slide 1: Q4 report 2020
Feb 25, 2021 Q4 report 2020 Göran Forsberg, CEO Bengt Jöndell, CFO
Slide 2: Safe Harbour Statement
Safe Harbour Statement Statements in the Investor Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known an
Slide 3: Presenters
Presenters GÖRAN FORSBERG, CEO BENGT JÖNDELL, CFO 3
Slide 4: Significant events
Significant events Fourth quarter • The first patient started treatment in the US phase 1 study evaluating combination therapy with CAN04 and pembrolizumab. • The recruitment of patients with pancreatic cancer for the CANFOUR phase 2a study was completed and positive interim results were presented.
Slide 5: I. Project Status
I. PROJECT STATUS
Slide 6: Cantargia – Opportunity to save lives and create value
Cantargia – Opportunity to save lives and create value Discovery Preclinical Project phase phase Phase I Phase II Phase III Commercial phase CAN04 ➢ Potentially more effective treatment against novel Pancreatic cancer Chemo combinations target in clinically validated Non-small cell lung cancer Chemo
Slide 7: Positive interim data: Pancreatic cancer
Positive interim data: Pancreatic cancer Non-small cell lung cancer Patient 1 2 3 4 5 6 7 8 9 0 Percent tumor reduction (RECIST 1.1) PR -50 -100 CR → CAN04 combination with gemcitabine/abraxane in 1st line PDAC → CAN04 in combination with gem/cis in 1st line chemotherapy NSCLC → 8 out of 20 evaluabl
Slide 8: CAN04 – Pancreatic cancer chemotherapy combinations
CAN04 – Pancreatic cancer chemotherapy combinations Discovery Preclinical Project phase phase Phase I Phase II Phase III Commercial phase CAN04 ➢ Encouraging interim data (gem/nab-pac) Pancreatic cancer Chemo combinations Non-small cell lung cancer ➢ Primary part (31 pt) fully Chemo combinations rec
Slide 9: CAN04 – NSCLC chemotherapy combinations
CAN04 – NSCLC chemotherapy combinations Discovery Preclinical Project phase phase Phase I Phase II Phase III Commercial phase CAN04 ➢ Encouraging interim data (gem/cis) Pancreatic cancer Chemo combinations Non-small cell lung cancer ➢ Recruitment of primary Chemo combinations analysis group (up to 3
Slide 10: CAN04 – Monotherapy safety and biomarkers
CAN04 – Monotherapy safety and biomarkers Discovery Preclinical Project phase phase Phase I Phase II Phase III Commercial phase CAN04 ➢ Phase I presented at ASCO 2019 Pancreatic cancer Chemo combinations Non-small cell lung cancer ➢ Phase IIa fully recruited Chemo combinations Pancreatic cancer ➢ Bi
Slide 11: CAN04 – Combination with immunotherapy
CAN04 – Combination with immunotherapy Discovery Preclinical Project phase phase Phase I Phase II Phase III Commercial phase CAN04 ➢ Pembrolizumab combination: Started H2 Pancreatic cancer Chemo combinations 2020 Non-small cell lung cancer Chemo combinations ➢ Recruitment of up to 18 Pancreatic canc
Slide 12: CAN04 – New cancer forms outside PDAC and NSCLC
CAN04 – New cancer forms outside PDAC and NSCLC Discovery Preclinical Project phase phase Phase I Phase II Phase III Commercial phase CAN04 ➢ Broadening into new cancer forms including Pancreatic cancer Chemo combinations TNBC Non-small cell lung cancer Chemo combinations ➢ Combination with Pancreat
Slide 13: CAN10 – remaining steps before start of clinics
CAN10 – remaining steps before start of clinics Discovery Preclinical Project phase phase Phase I Phase II Phase III Commercial phase CAN04 Pancreatic cancer Chemo combinations Non-small cell lung cancer Chemo combinations Pancreatic cancer Non-small cell lung cancer Monotherapy Solid tumors ICI com
Slide 14: II. Finance
II. FINANCE
Slide 15: Financial overview full year 2020
Financial overview full year 2020 Operating expenses ( = operating loss) • Increased with 56% to SEK 173.9 (111.6) M R&D • 91 (87) % of operating expenses • CAN04, Clinical studies and CMC • CAN10, Preclinical studies • Personell, 18 (11) FTE as of December 31 Cash flow • Cash flow from operating ac
Slide 16: Financial position as of December 31, 2020
Financial position as of December 31, 2020 • Strong financial position after two directed share issues • Raising in total SEK 973.8 (106.0) M before transaction costs SEK 39.9 (8.0) M • Solidity 96 (86) % • Available funds (=cash & bank + short term investments) SEK 903.4 (149.9) M 16
Slide 17: Cantargia has several near-term value inflection points
Cantargia has several near-term value inflection points Upcoming news flow CAN04 → Phase IIa combination results PDAC and NSCLC → Next steps combination therapy PDAC and NSCLC → Phase IIa biomarker/biopsy results → Start new clinical trials • FOLFIRINOX combination PDAC • Basket trial NSCLC and new
Slide 18: III. Q & A
III. Q & A